Oaktree Acquisition Corp. III Life Sciences reported its financial results for the second quarter of 2025, revealing a net income of $1,874,343 for the three months ended June 30, 2025, compared to a net income of $3,533,134 for the six-month period. The company generated $2,144,153 in interest income from cash held in its trust account, offset by general and administrative expenses of $269,810 for the quarter. This marks a significant increase in net income compared to the previous fiscal period, attributed primarily to the interest earned on the trust account, which totaled $4,247,746 for the six months ended June 30, 2025.
As of June 30, 2025, Oaktree Acquisition Corp. III reported total assets of $199,175,668, a slight increase from $195,250,622 at the end of the previous fiscal year. The company’s cash held in the trust account rose to $197,576,768, up from $193,579,022. However, the company also reported an accumulated deficit of $6,539,621, reflecting ongoing operational costs without any revenue generation, as it has yet to complete a business combination since its inception in June 2024.
In terms of operational developments, Oaktree Acquisition Corp. III has not yet identified a specific target for its initial business combination. The company continues to focus on its strategic goal of merging or acquiring a business within the life sciences sector. The company’s management has indicated that it will utilize the funds in the trust account primarily for this purpose, while also managing operational expenses. The company’s employee headcount remains stable, with no significant changes reported in staffing.
The company has also undergone a leadership change, with Thomas Sweeney appointed as the new Chief Financial Officer following the resignation of Courtney Conigliaro on June 3, 2025. This transition is part of the company’s ongoing efforts to strengthen its management team as it prepares for future business activities. Looking ahead, Oaktree Acquisition Corp. III remains focused on identifying suitable business combination opportunities, although it acknowledges the challenges posed by current market conditions and geopolitical uncertainties that could impact its plans. The company has sufficient liquidity to support its operations for at least the next year, but it cannot guarantee the successful completion of a business combination.
About Oaktree Acquisition Corp. III Life Sciences
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.